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SUMMARY
Prostate cancer is recognised to be the commonest type of malignancy in the male 
in many parts of the world. Prostate cancer has a propensity to metastasize to bone, 
however metastasis to the jaw is uncommon and indeed among metastatic tumours 
of the jaws which are a rarity, only about 9% originate from a prostatic primary. We 
report a case of histologically proven metastatic prostate cancer to the right mandible 
which necessitated a hemi-mandibulectomy in order to improve the patient’s quality 
of life. 
INTRODUCTION
Prostate cancer is now the commonest type of malignancy 
in the male in many parts of the world (1). In patients 
with clinically detected prostate cancer, about 10 – 20 % of 
them are found to have metastatic disease on presentation 
(2). Distant spread may also follow progression of the 
disease after initial therapy (3). Although prostate cancer 
has a propensity to metastasize to bone (4,5), the sites of 
predilection are usually the vertebrae, ribs, long bones 
and the skull. Metastasis to the jaw is uncommon (6). 
Indeed among metastatic tumours of the jaws which are 
a rarity, only about 9% originate from a prostatic primary 
(7). The most commonly affected bone is the mandible 
(60 – 80% of cases) with the most frequent location being 
the molar region (6,8).
 In about 30% of cases, the oral lesion provides 
the first indication of the presence of a previously 
undiscovered primary cancer (6-8). The purpose of 
this report is therefore to highlight the occurrence 
of this rare condition and also emphasize the need 
to consider metastatic neoplasm in the differential 
diagnosis of jaw lesions. 
CASE REPORT
A 64-year-old man presented initially in March 1999 
with lower urinary tract symptoms suggestive of 
bladder outlet obstruction. Digital rectal examination 
(DRE) showed an enlarged prostate gland (approx.100 
g) which felt largely benign except for a small nodule 
in the right lobe. Laboratory investigations showed an 
elevated prostate specific antigen (PSA) of 28ng/ml. 
His basic haematological and biochemical profiles as 
well as urinalysis and urine culture were normal. 
 Histopathological examination of a digitally guided 
transrectal tru-cut biopsy of the prostate showed prostatic 
adenocarcinoma with a Gleason score of 8. Shortly 
thereafter he developed acute urinary retention and 
had to be catheterised. Staging investigations including 
chest X-ray, liver function test, abdominal ultrasound 
and skeletal survey were normal. An abdomino-pelvic 
computerised tomographic (CT) scan could not be done 
because the machine was non-operational at the time of 
the patient’s initial evaluation. 
 In January 2001, he underwent transvesical 
prostatectomy to relieve his outflow obstruction and 
bilateral total orchidectomy for hormonal control of 
his cancer. Prior to the orchidectomy, the side effects 
of androgen deprivation therapy including loss of 
libido, erectile dysfunction, hot flushes and body 
composition changes were discussed in detail with 
the patient. The operation was undertaken after the 
patient and his spouse upon due consideration and 
counselling had consented to it. Postoperatively he 
did well and subsequently resumed normal work and 
activity. By May 2001, his PSA had dropped to 1.5ng/
ml. He was reviewed at regular intervals thereafter. In 
February 2003, his PSA was noted to be 5.5ng/ml. He 
was asymptomatic at the time and DRE showed no 
abnormality. In view of the essentially normal rectal 
findings, it was decided to await a repeat of the serum 
PSA before any further action. However in July 2003, 
he reported at our Maxillofacial surgery clinic with a 
four month history of a right jaw swelling. There was 
associated toothache at the onset and initial management 
at a peripheral health centre had resulted in two of his 
teeth on the same side being extracted. The swelling 
was hard and involved the whole body of the right 
mandible. An incisional biopsy of the mass was found 
on histopathological examination to be metastatic 
adenocarcinoma. A CT scan done subsequently, showed 
spread also to the right mastoid and the parietal brain. 
His PSA at this stage was 13.8 ng/ml. He was then 
put on the antiandrogen bicalutemide 150mg daily, to 
maximise his androgen deprivation therapy.
 He successfully underwent a right hemi-
mandibulectomy and reconstruction using titanium 
plate in September 2003. This was the patient’s choice 
of management option to improve his appearance. 
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A removable partial denture was also provided. He 
remained well until March 2004 when he presented 
with a three day history of bleeding from the right ear. 
Again DRE on this occasion was essentially normal. 
Serum PSA and testosterone levels were 26.5 ng/ml 
and 4.3 nmol/l (normal: 8 – 35) respectively. Subsequent 
ear, nose and throat consultation showed extention 
of the mastoid secondaries into the external auditory 
canal. The ear lesions were managed conservatively 
first with magnesium sulphate wick and then otosporin 
ear drops producing symptomatic relief.
 At his last review in December 2004, he was well 
and free from ear bleeding. However he succumbed 
finally to the disease in November 2005.
DISCUSSION
Metastatic tumours to the oral region are uncommon 
and account for approximately 1% of all malignant 
oral tumours. Although the method of spread is 
haematogenous, the exact mechanism of tumour 
metastasis from distant sites to the jaw bones is not 
fully understood. It has been suggested that some 
tumour cells are more “selective” in metastatic colony 
formation, hence they bypass nearby proximal organs 
and selectively settle in a specific distal organ (9). Another 
possible explanation is that active bone marrow which 
could be present in the posterior area of the mandible in 
some patients may serve to attract tumour cells (10). The 
primary site of metastatic tumours show some gender 
variation. In the male, the lung, followed by the prostate 
are the most common primary sites while the breast is 
the most frequent site in females (8,11). 
 This case report has demonstrated the initial 
difficulty in diagnosing a metastatic jaw lesion. Firstly 
because its presentation may mimic odontogenic 
infections or even benign tumours clinically (6), 
and secondly it may be the first manifestation of an 
undiagnosed malignancy (6-8). Our patient’s initial 
presentation with toothache and swelling resulted in 
his initial management in a peripheral hospital by tooth 
extraction. In a review of 390 cases from the English 
language literature, Hirshberg et al (8) found that 
majority of male cases presented in the fifth and seventh 
decades of life. It is therefore reasonable to consider 
metastatic disease in the differential diagnosis of all 
males in that age bracket presenting with symptoms of 
pain and swelling or paraesthesia (numb chin syndrome 
or mental nerve neuropathy) (12). 
 From the urological standpoint, a couple of features 
of this case are worth noting. The decision to manage his 
acute urinary retention (following his transrectal biopsy) 
by an open prostatectomy was based on the fact that 
he had a big gland (approx. 100g) on DRE which felt 
clinically benign except for a small nodule in the right 
lobe. The other notable feature is that from the time 
his PSA began to rise after achieving a PSA nadir of 1.5 
ng/ml following androgen deprivation therapy, to the 
time the jaw lesion appeared, his prostatic remnant felt 
essentially normal on DRE, with no evidence of local 
tumour progression. It is difficult to explain the lack of 
abnormal rectal findings in the presence of metastatic 
spread of the disease. Perhaps the metastatic potential 
of the tumour did not allow enough time for palpable 
local changes of progression to occur after the tumour 
had escaped from hormonal control.
 Most researchers agree that the prognosis for this 
type of oral cancer is grave with average time of survival 
after diagnosis being less than 10 months (11,12). At 
the time of the jaw secondary, our patient’s prostate 
cancer had undoubtedly become hormone refractory. 
Treatment of hormone refractory prostate cancer has 
been largely unsuccessful in prolonging survival 
although some recent studies have shown some promise 
with the use of taxanes (13). Despite our patient’s 
unfavourable prognosis, a hemi-mandibulectomy was 
deemed appropriate because of local symptoms in order 
to improve his quality of life.
In conclusion, metastatic disease to the jaws although 
rare, must always be considered in the differential 
diagnoses of common oral symptoms such as pain, 
swelling and paraesthesia, especially in the elderly. 
Operative intervention may be necessary in some 
patients in order to improve their quality of life.  
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